NBI-1117568

Last updated
NBI-1117568
Clinical data
Other namesHTL-0016878; NBI-1117568; NBI-568
Routes of
administration 		Oral
Drug class Muscarinic acetylcholine M4 receptor agonist

NBI-1117568 (former developmental code name HTL-0016878) is an investigational antipsychotic drug for schizophrenia that was out-licensed Nexera Pharma in to Neurocrine Biosciences, a United States-based pharmaceutical company. [1] [2] It is administered orally. [3] [4]

Contents

Overview

It is a selective muscarinic acetylcholine M4 receptor agonist that indirectly modulates dopamine as the basis for its putative improvement of schizophrenia. [3] In April 2016, the compound was out-licensed to Allergan, an Irish pharmaceutical company. By September 2017, it had advanced to Phase I clinical trial for the indication of "neuropsychiatric symptoms associated with Alzheimer's disease and other dementias" [5] However, in May 2020, Allergan was acquired by AbbVie, and due to AbbVie's pipeline business decisions, the license was returned to Nexceris in January 2021. [6] In November 2021, the compound was newly out-licensed to Neurocrine Biosciences, a U.S. pharmaceutical company. [2] It has been under development as a treatment for schizophrenia, and as of September 2024, Phase II clinical trials have been completed. [7] [8]

History

Clinical trials

Phase II clinical trial

The Phase II clinical trial was conducted in 15 sites across the U.S. with 200 adult patients diagnosed with schizophrenia. [16] The primary endpoint was assessed by the change in the total score of the Positive and Negative Syndrome Scale (PANSS) after six weeks of treatment. The 20 mg once-daily group showed a statistically significant improvement of 7.5 points compared to the placebo group (improvement of 18.2 points from baseline, p = 0.011, effect size = 0.61). [17] However, the 40 mg once-daily group, 60 mg once-daily group, and 30 mg twice-daily group did not show statistically significant differences compared to the placebo group (p-values: 40 mg group: 0.282, 60 mg group: 0.189, 30 mg twice-daily group: 0.090). [17]

Market reaction to phase II clinical trial

With a PANSS improvement of 7.5, NBI-111758 lagged behind xanomeline/trospium (KarXT) (Karuna Therapeutics) with 8.4 and emraclidine (Cerevel Therapeutics) with 12.7, both of which were in clinical trials at the same time. Moreover, the lack of dose-dependency led to disappointment in the stock market. [18] Neurocrine Biosciences' share price dropped 19% on the day following the announcement of the Phase II clinical trial results. [19]

See also

Related Research Articles

<span class="mw-page-title-main">Recruit (company)</span> Japanese human resources company

Recruit Holdings Co., Ltd., also known as RGF outside Japan, is a human resources holding company headquartered in Tokyo, Japan. The company was founded by Hiromasa Ezoe (江副浩正), then an educational psychology student at the University of Tokyo, as Daigaku Shimbun Koukokusha in 1960. It was a spin-off from the Todai Shimbun.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

<span class="mw-page-title-main">Seiko Hashimoto</span> Japanese politician and sportswoman (born 1964)

Seiko Hashimoto is a Japanese politician, former speed skater and track cyclist. She has the most Olympic appearances of any Japanese athlete except Noriaki Kasai, representing her native country in four consecutive Winter Olympics from 1984 to 1994 and in three consecutive Summer Olympics from 1988 to 1996, making her a seven time Olympian. On top of her Olympic career, she is the mother of six children while working in politics and other leadership positions. She is currently a member of the House of Councillors from the Liberal Democratic Party, and served as the President of the Japan Skating Federation from 2006 to 2019.

<span class="mw-page-title-main">Junya Ogawa</span> Japanese politician

Junya Ogawa is a Japanese politician of the Constitutional Democratic Party, and a member of the House of Representatives in the Diet. A native of Takamatsu, Kagawa and graduate of the University of Tokyo, he joined the Ministry of Home Affairs in 1994. Leaving the ministry in 2003, he ran unsuccessfully for the House of Representatives in the same year. Two years later, he ran again and lost for a second time. He ran for a third time in 2009 and was elected for Kagawa 1st district.

<span class="mw-page-title-main">Dempagumi.inc</span> Japanese female idol group

Dempagumi.inc is a Japanese female idol group from Akihabara, Tokyo. Their music generally follows the style of denpa song. All of its members are said to be former otaku.

Part-time job terrorism is a Japanese social phenomenon where part-time employees perform pranks and stunts, usually to share on social media. Stunts include climbing into ice cream freezers, or "planking" on counter-tops at fast-food restaurants. Although such pranks would not be seen as shocking in many cultures, they are considered disgraceful in Japanese culture.

The Yoshimoto New Star Creation, commonly called NSC or Yoshimoto Academy, is the comedy school established by Yoshimoto Kogyo in Japan.

<span class="mw-page-title-main">CyberAgent</span> Japanese digital advertising company

CyberAgent Inc. is a Japanese digital advertising company, which was founded in 1998 by Susumu Fujita and headquartered in Shibuya, Tokyo. It is owned by Susumu Fujita with 20.50% interest; Fujita is the representative director, while Yusuke Hidaka is the executive vice president.

<span class="mw-page-title-main">National Institute of Infectious Diseases (Japan)</span> Governmental research institute in Japan

The National Institute of Infectious Diseases is an institution of the Ministry of Health, Labour and Welfare. Its predecessor is the National Institute of Health, which was established in 1947.

The year 2023 in Japanese music.

U-Next is a Japanese over-the-top streaming service. It is majority-owned by U-Next Holdings and minority-owned by TBS Holdings and Hakuhodo DY Media Partners. It was launched in 2007 as GyaO Next and has since grown to become one of the largest streaming platforms in Japan, with 4.3 million registered subscribers as of May 2024. The service includes not only videos but also e-book services. U-Next was the second highest-grossing subscription video service in Japan as of 2022.

<span class="mw-page-title-main">TVer (streaming service)</span> Japanese video streaming service

TVer is a Japanese ad-supported video on demand (AVOD) service. It was established in October 2015, operated by Nippon TV, TV Asahi, TBS Television, TV Tokyo and Fuji Television and others. It is a service that offers free internet streaming of TV programs after they have aired, with the availability period typically lasting about one week from the end of the broadcast to the next episode's airing. Similar to traditional TV broadcasts, commercials are shown during the programs. TVer offers content from 115 stations across Japan as of October 2020 and provides access to 650 programs as of 2023.

<span class="mw-page-title-main">2023 visit by Fumio Kishida to Ukraine</span>

On 21 March 2023, Fumio Kishida, the Prime Minister of Japan, visited Ukraine. This was the first visit to Ukraine by the Prime Minister since the beginning of the Russian invasion of Ukraine.

<span class="mw-page-title-main">2024 Liberal Democratic Party (Japan) presidential election</span> Party presidential election

The 2024Liberal Democratic Party presidential election was held on 27 September 2024 to elect the next president of the Liberal Democratic Party of Japan for a three-year term.

<span class="mw-page-title-main">Kyoto Aquarium</span> Aquarium in Kyoto Prefecture, Japan

Kyoto Aquarium(京都水族館) is an aquarium located in Umekoji Park in Kyoto City, Kyoto Prefecture's Shimogyo Ward, Japan.

The Institute of Science Tokyo is a public university in Tokyo, Japan. It was officially established on 1 October 2024, by a merger between the Tokyo Institute of Technology and Tokyo Medical and Dental University. The main campus is located in Ookayama, Meguro, with satellite campuses in Yokohama, Minato-ku, Bunkyo-ku, and Ichikawa.

<span class="mw-page-title-main">Hiroyuki Yoshikawa</span> Japanese engineer

Hiroyuki Yoshikawa (吉川弘之) is a Japanese engineer. He specialises in precision engineering and general design theory. He served as the 25th president of the University of Tokyo and the 20th and 21st president of the Science Council of Japan. He is a member of the Japan Academy and a recipient of the Grand Cordon of the Order of the Sacred Treasure.

<span class="mw-page-title-main">Shinji Ishimaru</span> Japanese politician

Shinji Ishimaru is a Japanese politician who has served as Mayor of Akitakata from 2020 until his resignation in 2024. Ishimaru obtained national prominence as mayor in 2022 after a video of him scolding members of the city council for sleeping during a meeting went viral on social media, with the video gaining 13 million views on YouTube. Ever since then, he has gained a large internet following, especially on Twitter with his vocal political opinions and by documenting his frequent clashes with local political opponents.

<span class="mw-page-title-main">Keita Motoji</span> Japanese kimono retailer (born 1984)

Keita Motoji is a Japanese Kimono retailer. Keita directs the kimono brand Ginza Motoji, founded by his father Motoji Koumei in 1974.

<span class="mw-page-title-main">2024 Hyogo gubernatorial election</span> Election in Japan

The 2024 Hyōgo gubernatorial election will take place on 17 November 2024 to elect the governor of Hyōgo, Japan.

References

  1. ↑ "HTL 0016878". AdisInsight. 2 September 2024. Retrieved 21 October 2024.
  2. 1 2 "ニューロクライン社との統合失調症およびその他の精神神経疾患を対象とした新規ムスカリン受容体作動薬に関するライセンス契約締結のお知らせ". プレスリリース・ニュースリリース配信シェアNo.1｜PR TIMES. PR TIMES. 2021-11-22. Retrieved 2024-09-17.
  3. 1 2 "ネクセラファーマ株価6.5%高 薬候補で毒性試験成功 - 日本経済新聞". 日本経済新聞 電子版. 日本経済新聞社. 2024-04-17. Retrieved 2024-09-17.
  4. ↑ "当社提携先のニューロクライン社が、統合失調症を対象にしたNBI-1117568の第II相臨床試験の開始を発表［そーせいグループ］ | NIKKEI COMPASS - 日本経済新聞". 日経コンパス (in Japanese). 日本経済新聞社. 2022-10-28. Retrieved 2024-09-17.
  5. ↑ "アルツハイマー病等の主要症状の治療薬として開発中の新薬候補、 選択的ムスカリンM4受容体作動薬の第I相臨床試験で最初の被験者への投与を実施" (PDF). ネクセラファーマ（旧そーせいグループ株式会社）. 2017-09-01. Retrieved 2024-09-17.
  6. ↑ "ムスカリン作動薬プログラムのグローバルな研究開発権・販売権が返還". プレスリリース・ニュースリリース配信シェアNo.1｜PR TIMES. PR Times. 2021-01-05. Retrieved 2024-09-17.
  7. ↑ 日経バイオテクONLINE (2024-09-02). "ネクセラファーマ、統合失調症治療薬候補 NBI-1117568の第II相臨床試験の良好な結果によりニューロクライン社より35百万米ドルのマイルストンを受領". 日経バイオテクONLINE. 日本経済新聞社. Retrieved 2024-09-17.
  8. ↑ "ネクセラ---大幅反落、ニューロクラインの株価下落に追随売り | 個別株 - 株探ニュース". kabutan.jp. MINKABU THE INFONOID, Inc. 2024-08-29. Retrieved 2024-09-17.
  9. 1 2 "ムスカリン作動薬プログラムのグローバルな研究開発権・販売権が返還". プレスリリース・ニュースリリース配信シェアNo.1｜PR TIMES. PR Times. 2021-01-05. Retrieved 2024-09-17.
  10. ↑ "アルツハイマー病等の主要症状の治療薬として開発中の新薬候補、 選択的ムスカリンM4受容体作動薬の第I相臨床試験で最初の被験者への投与を実施" (PDF). ネクセラファーマ（旧そーせいグループ株式会社）. 2017-09-01. Retrieved 2024-09-17.
  11. ↑ "ニューロクライン社との統合失調症およびその他の精神神経疾患を対象とした新規ムスカリン受容体作動薬に関するライセンス契約締結のお知らせ". プレスリリース・ニュースリリース配信シェアNo.1｜PR TIMES. PR TIMES. 2021-11-22. Retrieved 2024-09-17.
  12. ↑ "当社提携先のニューロクライン社が、統合失調症を対象にしたNBI-1117568の第Ⅱ相臨床試験の開始を発表". プレスリリース・ニュースリリース配信シェアNo.1｜PR TIMES. PR TIMES. 2022-10-28. Retrieved 2024-09-17.
  13. ↑ "ネクセラファーマ株価6.5%高 薬候補で毒性試験成功 - 日本経済新聞". 日本経済新聞 電子版. 日本経済新聞社. 2024-04-17. Retrieved 2024-09-17.
  14. ↑ 日経バイオテクONLINE (2024-09-02). "ネクセラファーマ、統合失調症治療薬候補 NBI-1117568の第II相臨床試験の良好な結果によりニューロクライン社より35百万米ドルのマイルストンを受領". 日経バイオテクONLINE. 日本経済新聞社. Retrieved 2024-09-17.
  15. ↑ "ネクセラ---大幅反落、ニューロクラインの株価下落に追随売り | 個別株 - 株探ニュース". kabutan.jp. MINKABU THE INFONOID, Inc. 2024-08-29. Retrieved 2024-09-17.
  16. ↑ "Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia". ニューロクライン. 2022-10-27. Retrieved 2024-09-17.
  17. 1 2 "ネクセラファーマ[4565]：ニューロクライン社との提携プログラムである統合失調症治療薬候補NBI-1117568の第2相臨床試験で良好な結果 2024年8月28日(適時開示) ：日経会社情報DIGITAL：日本経済新聞". 日本経済新聞 電子版. 日本経済新聞社. Retrieved 2024-09-17.
  18. ↑ "Nxera Pharma Official IR Blog 「ニューロクライン社から35百万米ドルのマイルストン受領」". soseiheptares.blogspot.com. ネクセラファーマ. 2024-09-02. Retrieved 2024-09-19.
  19. ↑ "Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results". Zacks Investment Research. Zacks Investment. 2024-08-29. Retrieved 2024-09-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.